Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Voyager Therapeutics (VYGR) Gross Profit: 2015-2025

Historic Gross Profit for Voyager Therapeutics (VYGR) over the last 11 years, with Sep 2025 value amounting to $13.4 million.

  • Voyager Therapeutics' Gross Profit fell 45.59% to $13.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $31.4 million, marking a year-over-year decrease of 80.84%. This contributed to the annual value of $80.0 million for FY2024, which is 68.00% down from last year.
  • According to the latest figures from Q3 2025, Voyager Therapeutics' Gross Profit is $13.4 million, which was up 157.69% from $5.2 million recorded in Q2 2025.
  • Over the past 5 years, Voyager Therapeutics' Gross Profit peaked at $150.5 million during Q1 2023, and registered a low of -$1.6 million during Q4 2022.
  • Moreover, its 3-year median value for Gross Profit was $13.4 million (2025), whereas its average is $32.3 million.
  • Its Gross Profit has fluctuated over the past 5 years, first tumbled by 105.52% in 2022, then surged by 22,769.30% in 2023.
  • Over the past 5 years, Voyager Therapeutics' Gross Profit (Quarterly) stood at $28.1 million in 2021, then slumped by 105.52% to -$1.6 million in 2022, then surged by 5,910.39% to $90.1 million in 2023, then crashed by 93.03% to $6.3 million in 2024, then crashed by 45.59% to $13.4 million in 2025.
  • Its Gross Profit stands at $13.4 million for Q3 2025, versus $5.2 million for Q2 2025 and $6.5 million for Q1 2025.